Latest Ratios: P/E Ratio -6.5x · EV/EBITDA N/A · ROE -14.9%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $50M | $65M | $113M | $38M | $123M | $119M | $63M | $57M | $105M | $68M | $63M |
| Enterprise Value | $29M | $44M | $92M | $16M | $99M | $105M | $50M | $51M | $92M | $60M | $58M |
| P/E Ratio → | -6.47 | — | 16.88 | 79.19 | 5.08 | 28.88 | — | — | — | — | — |
| P/S Ratio | 1.82 | 2.36 | 2.71 | 1.57 | 2.77 | 4.41 | 6.62 | 2.11 | 3.96 | 3.32 | 4.26 |
| P/B Ratio | 1.03 | 1.35 | 2.03 | 0.79 | 2.57 | 4.58 | 2.95 | 2.05 | 3.95 | 5.85 | 4.13 |
| P/FCF | 150.74 | 195.73 | — | — | — | — | — | — | — | — | — |
| P/OCF | 94.78 | 123.07 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.59 | 2.19 | 0.66 | 2.22 | 3.88 | 5.21 | 1.86 | 3.49 | 2.94 | 3.92 |
| EV / EBITDA | — | — | 10.77 | 202.82 | 6.44 | 22.15 | — | — | — | — | — |
| EV / EBIT | — | — | 11.34 | — | 6.66 | 25.44 | — | — | — | — | — |
| EV / FCF | — | 131.26 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.2% | 43.2% | 58.4% | 57.6% | 66.5% | 62.8% | 54.8% | 64.4% | 64.0% | 67.0% | 66.5% |
| Operating Margin | -37.5% | -37.5% | 19.4% | -1.6% | 33.3% | 15.2% | -86.0% | -7.2% | -7.6% | -18.1% | -2.5% |
| Net Profit Margin | -28.1% | -28.1% | 15.9% | 2.0% | 54.4% | 15.2% | -71.4% | -6.2% | -7.7% | -18.0% | -2.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.9% | -14.9% | 12.7% | 1.0% | 65.5% | 17.3% | -27.6% | -6.2% | -10.6% | -27.5% | -3.3% |
| ROA | -13.4% | -13.4% | 11.5% | 0.9% | 54.5% | 13.7% | -21.1% | -4.8% | -7.8% | -19.6% | -2.4% |
| ROIC | -25.3% | -25.3% | 19.9% | -1.1% | 63.0% | 31.4% | -42.2% | -8.4% | -16.9% | -39.7% | -4.7% |
| ROCE | -19.7% | -19.7% | 15.3% | -0.8% | 39.4% | 16.7% | -30.7% | -6.8% | -10.3% | -27.5% | -3.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.06 | 0.05 | — | 0.19 | — |
| Debt / EBITDA | — | — | 0.07 | 9.91 | 0.07 | 0.05 | — | — | — | — | — |
| Net Debt / Equity | — | -0.44 | -0.38 | -0.46 | -0.51 | -0.55 | -0.63 | -0.24 | -0.47 | -0.67 | -0.33 |
| Net Debt / EBITDA | — | — | -2.52 | -283.10 | -1.60 | -3.02 | — | — | — | — | — |
| Debt / FCF | — | -64.47 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | 7415.50 | 4121.00 | -487.29 | — | -11.91 | -52.87 | -14.84 |
Net cash position: cash ($22M) exceeds total debt ($680000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.72 | 9.72 | 9.64 | 11.76 | 6.92 | 5.24 | 5.18 | 5.26 | 5.30 | 2.53 | 4.58 |
| Quick Ratio | 6.63 | 6.63 | 7.93 | 8.94 | 6.46 | 4.94 | 4.27 | 4.79 | 5.03 | 2.36 | 4.24 |
| Cash Ratio | 4.68 | 4.68 | 3.75 | 5.50 | 3.32 | 2.43 | 3.07 | 2.39 | 2.55 | 1.58 | 3.15 |
| Asset Turnover | — | 0.52 | 0.67 | 0.45 | 0.78 | 0.84 | 0.34 | 0.74 | 0.79 | 1.09 | 0.78 |
| Inventory Turnover | 1.07 | 1.07 | 1.72 | 0.87 | 4.26 | 5.72 | 0.98 | 3.24 | 5.84 | 5.79 | 3.96 |
| Days Sales Outstanding | — | 80.23 | 172.26 | 159.21 | 141.79 | 163.72 | 143.91 | 187.58 | 181.57 | 87.90 | 76.36 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 4.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 5.9% | 1.3% | 19.7% | 3.5% | — | — | — | — | — |
| FCF Yield | 0.7% | 0.5% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.6% | 0.5% | 0.0% | 0.1% | 2.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% |
| Total Shareholder Yield | 0.6% | 0.5% | 0.0% | 0.1% | 2.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 4.0% |
| Shares Outstanding | — | $16M | $16M | $16M | $17M | $17M | $16M | $16M | $14M | $13M | $12M |
Reimbursement and sales volatility
According to current market data, Sensus Healthcare trades at a price-to-sales ratio of 1.82, which, when viewed alongside a negative TTM P/E of -6.47, suggests that investors are pricing the firm as a distressed asset rather than a growth-oriented medical technology company with long-term potential.
The current valuation appears to reflect deep skepticism regarding the company's ability to return to historical growth levels. Given the significant revenue contraction, the P/S multiple may be artificially supported by the company's cash-rich balance sheet rather than its underlying operational earning power.
Based on reported financial figures, Sensus Healthcare's ROIC has deteriorated from a peak of 16.3% in 2023Q4 to -12.0% in 2026Q1, indicating that the company is currently failing to generate positive returns on its invested capital as operating losses mount and asset turnover slows significantly.
The sharp decline in ROIC highlights the difficulty of maintaining a high-fixed-cost business model during a period of shrinking demand. This trend suggests that the company's capital allocation into R&D and sales infrastructure is not currently yielding the necessary productivity to sustain shareholder value.
As reported in recent quarterly filings, the company's cash conversion cycle has expanded to 559 days in 2026Q1, driven by a significant increase in days inventory outstanding to 582, which suggests that Sensus is struggling to move its high-cost medical hardware through the sales channel efficiently.
The dramatic lengthening of the cash conversion cycle indicates that capital is becoming trapped in unsold inventory, which poses a risk of future write-downs. This inefficiency is a primary contributor to the company's current cash burn and warrants close monitoring by investors concerned with liquidity.
Based on the most recent balance sheet data, Sensus Healthcare maintains a current ratio of 7.27, which provides a substantial liquidity cushion that appears to insulate the firm from immediate insolvency despite the ongoing negative operating margins and the volatility inherent in its capital equipment sales.
While the high current ratio suggests a fortress-like balance sheet, it also implies that a significant portion of the company's assets are tied up in cash or slow-moving inventory rather than being deployed for growth. This liquidity position is a double-edged sword that provides survival time but highlights a lack of productive investment opportunities.
The price-to-earnings ratio is frequently misapplied to Sensus Healthcare, as the company's current negative earnings and lumpy revenue recognition render this metric largely meaningless for assessing the underlying value of its specialized dermatology platform and its potential for long-term recurring revenue from service and disposable sales.
Investors should instead focus on the company's price-to-book ratio or its cash-adjusted enterprise value to better understand the floor of the business. Relying on P/E in a period of severe operating deleveraging obscures the company's true financial health and its ability to pivot toward a more sustainable, usage-based revenue model.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SRTS stock.
Sensus Healthcare, Inc.'s current P/E ratio is -6.5x. The historical average is 32.5x.
Sensus Healthcare, Inc.'s return on equity (ROE) is -14.9%. The historical average is -7.3%.
Based on historical data, Sensus Healthcare, Inc. is trading at a P/E of -6.5x. Compare with industry peers and growth rates for a complete picture.
Sensus Healthcare, Inc. has 43.2% gross margin and -37.5% operating margin.